Elutia Inc
- ELUT
- NASDAQ
- Biotechnology
- Drug-eluting Biomatrix
- Surgical Reconstruction Devices
- Women's Health/Cardiovascular
$0.82
Today +2.67%Quote Oct 19, 2026, 08:00 PM UTC
−6.59%over the last month
Max drawdown −15.4%From 1-month high −8.6%3 months −14.6%
Our viewPro
The call stays with Pro
Verdict, why now, and the write-up open with Pro. New accounts get 14 days of Pro free.
About Elutia
Elutia Inc., a commercial-stage company, focuses on developing drug-eluting biomatrix products for use in surgical reconstruction and related applications. The company operates in two segments, Women’s Health and Cardiovascular.
Where the money comes from
Q2 2026 revenue $2.4M
- Women's Health$1.3M52.9%
- Cardiovascular$1.1M47.1%
Sector
Healthcare
Industry
Biotechnology
Exchange
NASDAQ
Employees
26
Founded
2015
Market value
$36.1M
Quote Oct 19
Floor
$0.79
2.5% below price
Resistance
$0.87
6.6% above price
Price vs analyst targets
5 analysts
Lowest target
$5.00Highest target
$10.50
$5.00Highest target
$10.50
- Price $0.82
- Average target $8.88
- Analysts' target range
The price is below even the lowest analyst target. Analysts' average target sits about 989% higher. Their range is wide.
The call stays with Pro
7 locked chapters- What to do with this namePro
- Why nowPro
- Why this stockPro
- Section write-upsPro
- Story timelinePro
- News briefPro
- Ask about ELUTPro
Verdict, why now, and the write-up open with Pro. New accounts get 14 days of Pro free.
Log in — 14 days free